Genmab A/S revenue for the last year amounted to 2.38 B USD, the most of which — 2.39 B USD — came from its highest performing source at the moment, Antibody Therapeutics, the year earlier bringing 2.06 B USD. The greatest contribution to the revenue figure was made by Denmark — last year it brought Genmab A/S 2.33 B USD, and the year before that — 2.06 B USD.